$ACCO

ACCO Brands' Price Target Lowered by Barrington Research | ACCO Stock News

Barrington Research has maintained its "Outperform" rating for ACCO Brands (ACCO) but lowered its price target from $6.00 to $5.00, representing a 16.67% decrease. This adjustment reflects current market evaluations and company performance, while still indicating confidence in ACCO Brands' potential. Wall Street analysts forecast an average target price of $8.33 for ACCO, implying a significant upside from its current price, with a consensus "Buy" status from brokerage firms.

Original reporting
GuruFocus · GuruFocus News
Published Mar 13, 2026, 4:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Mar 13, 2026, 5:00 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$ACCO
Bearish
medium confidence
Mentioned
$ACCO
alphai data visualization · based on GuruFocus
Decision brief

The 30-second read

$ACCOBearishMed
01

Why it matters

The target reduction signals short-term caution, but long-term prospects remain supported by analyst consensus and industry fundamentals.

02

Market read

The news is relevant to traders and investors holding or considering ACCO stock, especially those with short-term trading horizons.

03

What to watch

Potential for company-specific catalysts or industry-wide improvements that could offset the negative outlook.

Timing: short-term (next 1-3 months)

Background

Barrington Research's adjustment reflects recent market evaluations and company performance concerns, but maintains an overall positive rating.

Company-level read

Ticker impact

$ACCOBearishMedium confidence
Context

The news directly pertains to ACCO Brands, impacting its stock outlook.

Expected impact

Potential short-term decline or sideways movement due to the lowered price target, but long-term upside remains possible given analyst consensus.

Evidence & confidence

The reduction in the price target reflects short-term caution, but overall analyst sentiment remains positive, suggesting limited downside risk.

Market effects

The retail and office supplies sector may experience slight negative sentiment due to the target reduction, but overall sector outlook remains stable.

Limited regional impact; primarily affects investors and traders focused on U.S. equities.

Low; the news is specific to a U.S.-based company and does not significantly influence global markets.

Counterpoint

The lowered price target may be an overreaction; fundamentals and long-term analyst consensus suggest the stock could rebound to higher levels.

Key entities

  • ACCO Brands

    A manufacturer of office and school supplies.

  • Barrington Research

    An investment research firm providing stock ratings and target prices.

Related articles

$ACCOHighAI 9/10

ACCO to Buy Trust

ACCO Brands (NYSE: ACCO) agreed to buy Trust, a European computer and gaming accessories provider, from Egeria. Trust, founded in 1983, offers a wide range of products and operates in Europe and Latin America. ACCO's CEO Tom Tedford stated the acquisition aligns with their focus on high-growth technology peripherals, aiming for $500M in annual sales in this category.

$ACCOMedAI 8/10

ACCO Brands To Acquire Computer And Gaming Accessories Firm Trust From Egeria For Undisclosed Sum

ACCO Brands (ACCO) said it will acquire Trust, a European computer and gaming accessories provider, from Egeria for an undisclosed price. ACCO expects the deal to expand higher-growth peripherals and to deliver $5 to $8 million in cost synergies within 18 months. Funding will come from borrowings under its revolving credit facility. Closing is targeted for late Q3 or early Q4; shares were $4.26 premarket.

$ACCOMedAI 9/10

ACCO (ACCO) Q2 2026 Earnings Call Transcript

ACCO Brands (ACCO) reported Q2 2026 net sales of $415.1 million, up 5.1% on the EPOS acquisition and FX, while comparable sales fell 2.3%. Adjusted diluted EPS rose to $0.29. Management raised full-year net sales growth to 2% to 5% and adjusted EPS to $0.87 to $0.91, citing cost savings and EPOS integration. Q3 sales guidance is -1% to +2%.

$ACCOMed

ACCO BRANDS Corp (ACCO): Results of Operations and Financial Condition

ACCO BRANDS Corp (ACCO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 News Release ACCO BRANDS REPORTS SECOND QUARTER RESULTS • Reported net sales increased 5.1% to $415 million • Diluted EPS of $0.15; Adjusted diluted EPS of $0.29 • Raises full-year 2026 sales and adjusted EPS outlook • Reiterates full-year free cash flow of $75 milli

$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.